Click the Why column to see why an item matched the search.
Match | Type | Why |
---|
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange. | Academic Article |
Why?
|
Cooperative stabilization of transthyretin by clusterin and diflunisal. | Academic Article |
Why?
|
Effect of diflunisal on clusterin levels in ATTRwt amyloidosis. | Academic Article |
Why?
|
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. | Academic Article |
Why?
|
Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. | Academic Article |
Why?
|
The Diflunisal Trial: study accrual and drug tolerance. | Academic Article |
Why?
|
The use of diflunisal for transthyretin cardiac amyloidosis: a review. | Academic Article |
Why?
|
Effect of diflunisal on neurologic disease in familial transthyretin amyloidosis | Academic Article |
Why?
|
The diflunisal trial: update on study drug tolerance and disease progression. | Academic Article |
Why?
|
BU-Alnylam Diflunisal Research Collaboration | Grant |
Why?
|
Effect of Diflunisal on Familial Amyloidosis | Grant |
Why?
|
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. | Academic Article |
Why?
|
The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation. | Academic Article |
Why?
|
Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. | Academic Article |
Why?
|
A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis. | Academic Article |
Why?
|